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A number of DNA repair disorders are known to cause neurological problems. These disorders can
be broadly characterised into early developmental, mid-to-late developmental or progressive. The
exact developmental processes that are affected can influence disease pathology, with symptoms
ranging from early embryonic lethality to late-onset ataxia. The category these diseases belong to
depends on the frequency of lesions arising in the brain, the role of the defective repair pathway,
and the nature of the mutation within the patient. Using observations from patients and
transgenic mice, we discuss the importance of double strand break repair during neuroprogenitor
proliferation and brain development and the repair of single stranded lesions in neuronal function
and maintenance.
1 Introduction
The genome is constantly under attack from endogenous and exogenous genotoxic agents, and also
possesses an inherent level of instability [1]. Breaks can arise in one or both DNA strands, and
chemical adducts or crosslinks can arise on or between DNA bases [2-4]. In addition, the breakage
and repair of cellular DNA is also a necessary part of several cellular processes critical for cellular
growth and proliferation and for organismal development. Genome stability and maintenance
requires a number of overlapping biochemical pathways involving many different proteins, clustered
into specific DNA repair pathways. Loss of function of these proteins can lead to a variety of
disorders, with pathologies including growth and developmental defects, immunodeficiency, cancer,
neurodegeneration and ageing [5-7]. The association of DNA repair defects with both elevated
predisposition to cancer and to increased rates of neurodegeneration and ageing, sometimes in the
same genetic disease, is particularly intriguing, because cancer is a disease of excessive cell growth
and survival, whereas neurodegeneration is a disease of excessive cell dysfunction and death.
Opposite cellular end points can thus arise from defects in common or related processes [8]. In this
review we focus on DNA damage defective diseases associated with neurological dysfunction, and
attempt to rationalise the differences in underlying molecular defects between developmental and
neurodegenerative pathologies.
2 Brain development
Embryonic development involves waves of rapid cell division throughout the developing embryo,
followed by complex periods of migration and differentiation (Figure 1) [9]. During this time there is
a requirement for rapid and efficient mechanisms to fix transcription- and replication-associated
DNA breaks as well as naturally occurring oxidative breaks. Failure to repair these breaks may lead to
the accumulation of damage and cell death, resulting in neuronal loss at different stages of
development, depending on the frequency of DNA lesions and DNA damage signalling pathways.
Cortical development begins from around 5-7 gestation weeks in humans, during which there is a
rapid proliferation of neuroprogenitor cells from the ganglionic eminence (GE) of the ventricular
zone (VZ) through the neocortex [9, 10]. During this phase, there are tightly coordinated processes
of cell division, differentiation and migration from the site of neurogenesis to the cortical plate,
resulting in the generation of neurons that populate the neocortex [11, 12]. The brain then
undergoes a second phase of rapid neurogenesis during the latter phase of development. In humans
this occurs from 12 weeks gestation continuing through until around 6 months after birth [13, 14].
During this phase there is limited cell division within the VZ, but a burst of cell division, migration
and differentiation is initiated in the subventricular zone (SVZ) to generate a subpopulation of late-
born cortical neurons and interneurons [10]. In primates including humans this stage of
development is greatly expanded to generate the huge numbers of neuronal cells that populate the
cortex, suggesting that humans may be more susceptible to mutations in DNA repair defects than
rodent models [15]. Early cerebellar development follows a similar pattern of proliferation from the
VZ at around 9-10 weeks to form the Purkinje cell layer, but late-born granule cells are formed from
16 weeks, originating in the external granule layer (EGL) and moving inwards to the granule layer
past the maturing Purkinje cells. This wave of neurogenesis continues until around 7 months after
birth [9].
3 Double strand break repair and neurogenesis
Double strand break repair (DSBR) involves two distinct pathways (Figure 2) [16]: During G1 and
early S-phase, the dominant repair pathway involves the processing and ligation of non-homologous
DNA ends (non-homologous end joining; NHEJ). The principal components of NHEJ are DNA-
dependent protein kinase (DNA-PK), XRCC4, DNA ligase 4 (Lig4) and XLF/Cernunnos. Damaged DNA
termini are processed primarily by PNKP, TDP2, Artemis, aprataxin, or by one of several nucleases,
which prepare the DNA ends for ligation by Lig4 [17, 18]. Because of the processing events that
occur during NHEJ, loss of genetic information can occur. However, chromosomes are duplicated
during S-phase, and double strand breaks (DSBs) occurring in replicated DNA during S/G2 can be
repaired without loss of information by recombination between the damaged sister chromatid and
its homologous undamaged counterpart. This process, denoted homologous recombination (HR),
requires the activity of a number of proteins including BRCA1, BRCA2, XRCC2, XRCC3, and RAD51. HR
is initiated by nucleolytic resection of 5’-termini at DSBs in a CtIP/MRN-dependent dependent
manner, after which RAD51 facilitates invasion of the single-stranded 3’-tail into the homologous
sister chromatid, thereby enabling accurate repair of the DSB [19].
3.1.1 Non homologous end joining, Lig4 and NHEJ1 syndromes
Cells of the developing brain may switch in dependence from one DNA repair pathway to another,
depending on the phase of the cell cycle they are in (Figure 2) [20, 21]. In the early proliferative
phase there is a greater requirement for repair by HR, with the advantage that genetic information is
conserved. Loss of HR leads to embryonic lethality at a very early stage [22]. It is rare that
homozygous HR mutants survive to birth, and are usually only seen in patients with hypomorphic
mutations that retain sufficient HR activity to progress through this developmental stage. Patients
with such mutations suffer a spectrum of developmental disorders (which can include microcephaly)
such as those seen in Fanconi anaemia [23].
During migration and differentiation there is a greater dependence the NHEJ pathway, since cells
exiting the cell cycle and undergoing neuronal differentiation are in G1/G0. With no sister chromatid
available to undergo HR, NHEJ is the only DSB repair pathway available. Mutations in the NHEJ
pathway, therefore result in the loss of neuroprogenitor cells, loss of cortical neurons, and
microcephaly. The diseases associated with microcephaly listed in Figure 2 (green boxes) illustrate
that the latter phase of human brain development is particularly sensitive to loss of NHEJ capacity.
The structural components of the core NHEJ complex, KU70 and KU80, are essential for human cell
viability [24, 25] and there are no documented patients with mutations in these proteins. Other
components of the NHEJ complex (DNA-PKcs, Lig4 and XLF/Cernunnos) are also likely to be essential
for development, although patients carrying hypomorphic mutations in these proteins have been
reported [26-28]. Patients with Lig4 syndrome or severe combined immunodeficiency with
microcephaly, growth retardation, and sensitivity to ionizing radiation (NHEJ1 syndrome; mutated in
XLF/Cernunnos) suffer from microcephaly at birth and immunodeficiency, consistent with an
essential role for NHEJ in both brain development and VDJ recombination.
Mice with attenuated NHEJ show some symptoms consistent with those seen in humans, including
growth defects and immunodeficiency [29, 30]. Complete loss of NHEJ ligation factors XRCC4 and
LIG4 results in embryonic lethality in the latter stages of development, showing loss of cells following
defective lymphogenesis and massive apoptotic loss of neuronal cells in the cortex and hindbrain
[31-33]. The cause of neuronal loss is due to DSBs arising during the VZ and SVZ proliferative phases
and persisting during differentiation within the intermediate zone (IZ) [22, 33].
3.1.2 ATM and Ataxia telangiectasia
The PI 3-kinase-related kinases ATM and ATR detect genomic DSBs and phosphorylate a range of
targets (reviewed in [34, 35]) including cell cycle checkpoint proteins CHK1 and CHK2. These targets
suppress DNA replication origin firing and cell cycle progression, allowing cells to repair DSBs before
proceeding with cell division [36, 37]. Ultimately, if a number of DSBs persist then these kinases will
signal apoptosis by phosphorylation and stabilisation of p53. This is likely why neuronal loss in
mouse NHEJ mutants can be rescued by inactivation of ATM or p53 [38-40]. Since ATM signals cell
death in neurons with unrepaired DSBs, it is somewhat paradoxical that whilst loss of ATM activity
rescues the embryonic lethality of NHEJ-deficient mouse mutants, it results in ataxia telangiectasia
(A-T) in an otherwise normal background in humans.
A-T patients display symptoms indicative of compromised responses to DSBs, such as
immunodeficiency, sterility, radiosensitivity and cancer predisposition; the severity of the disease
usually correlating with the nature of the mutation, or the amount of active ATM protein within the
cells of the patient [41, 42]. Progressive neurodegeneration and ataxia is arguably the pathology that
impacts on quality of life most severely, though patients typically die from respiratory infections or
cancer [43]. Whereas NHEJ disorders appear to result from neuronal loss during corticogenesis, loss
of ATM function impacts primarily on neuronal maintenance in the cerebellum, brain stem and
spinal cord, with cell loss being particularly severe in the Purkinje cells, granule cells and molecular
layer [44-46]. The degenerative pathology of A-T may reflect the loss of ATM-mediated DSB
signalling during neurodevelopment and maintenance, and thus persistence of dysfunctional neural
cells into the adult brain that would otherwise commit to apoptosis, and/or may reflect the
requirement for ATM for repair of a subset of DSBs in neurons. In any case, loss of ATM results
primarily in neuronal dysfunction and ataxia, rather than developmental microcephaly. However, it
has been difficult to establish the precise consequence of ATM loss in the cerebellum, since Atm -/-
mice display only very mild, if any neurological defects [47, 48]. This suggests that the human brain
has a higher dependence on ATM than that of rodents.
3.1.3 ATR and ATR-Seckel syndrome
While ATM is activated by chromosomal DSBs, ATR is activated by stretches of RPA bound to single-
stranded DNA surrounding collapsed replication forks [49] and plays an important role in the
recovery from replication stress [50, 51]. The neurological phenotype of patients with ATR mutations
overlaps with NHEJ mutants more closely than does that of patients with mutations in ATM. This
may reflect a higher level of DNA damage-induced cell death in proliferating neurons during
neuronal development. Seckel syndrome shows characteristic growth defects, microcephaly and
mental retardation. However, the lack of severe radiosensitivity and immunological defects
distinguishes the mechanism of this disease from those described above [52, 53]. In mice, ATR is
essential for development [54, 55], but those carrying a Seckel syndrome mutation in humanized
ATR (ATRS) show the characteristic “bird-head” microcephaly seen in human Seckel syndrome
patients. In this model, the severe loss of neurons throughout the cerebellum, hippocampus and
cortex correlates with areas of neurogenesis in the developing brain, with cell death arising from
replication stress in the absence of ATR activity [56]. Similarly, a brain-specific ATR knockout
suggested that ATR signalling in the brain is critical during rapid waves of neuroprogenitor cell
division in the GE and cerebellum at late stages of development [57]. Other mutant proteins, such as
pericentrin and MCPH1 have been implicated in the cause of microcephaly through coupling ATR
signalling to the G2/M checkpoint via the centrosome [58, 59]. More specifically it is thought that
ATR/Chk1 signalling maintains neuronal stem cell populations during these developmental phases by
regulating the orientation of the mitotic spindle and controlling symmetric vs. asymmetric cell
division in the neuroprogenitor population [60] although other models for the role of centrosome in
brain development have been suggested [61].
3.1.4 The MRN complex, Nijmegen breakage syndrome and Ataxia telangiectasia-like
disorder
An important mediator of the DSB response is the MRN complex, comprising the proteins MRE11,
NBS1 (NBN) and RAD50. This complex is required for tethering the two ends of the DSB, nucleolytic
resection, and mediating the ATM/ATR damage response [62-66]. A number of hypomorphic
mutations in NBS1, MRE11 and RAD50 have been identified in patients with Nijmegen breakage
syndrome (NBS), A-T-like disorder (A-TLD) and NBS-like disorder (NBSLD) respectively. Patients with
these mutations show a phenotypic spectrum similar to other NHEJ disorders (microcephaly,
immunodeficiency, radiosensitivity and cancer predisposition) with varying severity that may reflect
the nature of the hypomorphic mutation on protein levels and DSB repair activity, or functional
differences between these proteins [67-72].
Because of MRN’s involvement in HR, NHEJ and damage signalling, it is not surprising that complete
loss of these components in mice results in early embryonic lethality [73-75]. Pathologies that
replicate some aspects of NBS and A-TLD have been seen in hypomorphic Nbs1 and Mre11 mouse
mutants, but these do not show neuropathology [76-78]. Shull et al attempted to address why NBS
results in microcephaly, whereas A-TLD results in an “AT-like” neurodegenerative phenotype [78].
Using ionising radiation (IR) or brain-specific Lig4 deletion (Lig4Nes-Cre) as a source of DSB damage, a
higher level of ATM and p53-dependent apoptosis was observed in mice mimicking NBS than those
mimicking A-TLD. This may indicate a more important role for Mre11 than Nbs1 in apoptotic
signalling via ATM, and thus greater impact on cell death during neurodevelopment, and/or that or
that loss of MRN activity is greater in mice mimicking A-TLD than those mimicking NBS [78].
In summary, the disorders described above illustrate the possible consequences of unrepaired DSBs
in the brain (figure 3). In cycling neuroprogenitors, ATR activates cell cycle checkpoints during
replication stress and mitosis and so reduced activity of this protein kinase may lead to excessive
DNA damage and cell death during neurodevelopment, resulting in microcephaly. Similarly, in NHEJ-
defective diseases, the elevated level of unrepaired DSBs may similarly lead to cell death and
microcephaly during neurodevelopment, particularly during G0/G1 in differentiating neurons, in
which HR-mediated repair is unavailable. In such cells, cell death occurs via ATM signalling, mediated
by the MRN complex. Consequently, If ATM signalling fails, neurons with unrepaired DSBs may
escape apoptosis and perhaps persist in a dysfunctional state, contributing to juvenile
neuropathology. The causes of late-onset progressive neuropathology in patients with A-T and A-TLD
are still under debate, but are probably due to the cumulative impact of defective DNA damage
signalling and repair during the lifetime of post-mitotic neurons [79].
4 Progressive neurodegeneration and cerebellar ataxia
Whilst DSBs are severe lesions that impact greatly on proliferating and differentiating cells, and
consequently on neurodevelopment, these lesions are relatively rare. In contrast, lesions on a single
strand of DNA, and in particular single-strand breaks (SSBs), arise 3 orders of magnitude more
frequently. Single-strand lesions are normally repaired rapidly by the SSBR and TC-NER pathways
(Figure 4), but if these pathways are defective, long-lived single-strand lesions can trigger cell death
by blocking the progression of RNA polymerases during transcription [80, 81]. This can impact on
proliferating cells, but the lesions can also be readily and accurately dealt with by specific repair
processes in S/G2 [82], and/or the damaged cells can be removed and readily replaced in
regenerative tissues. Consequently, defects in the repair of single-strand lesions are less likely to
cause developmental defects or microcephaly, unless the repair defect is so severe that alternative
repair and regenerative processes are overwhelmed. In post-mitotic cells, alternative S/G2 repair
pathways are absent, and the pathways shown in figure 4 are the primary if not only repair
pathways available. Consequently, attenuation or loss of those repair processes may result in
degeneration of non-cycling tissues. This perhaps explains the link between defects in the repair of
single-strand lesions, neurodegeneration, and premature aging.
4.1 NER, Cockayne syndrome and Xeroderma Pigmentosum
Proteins defective in the CS and XP complementation groups are collectively responsible for the
removal of cyclobutane pyrimidine dimers (CPDs), 6-4 photoproducts (6-4 PPs), bulky adducts and
oxidative base damage from the DNA using nucleotide excision repair (NER) [83-85]. In non-
transcribed regions, these helix-distorting lesions are detected by HR23B-XPC and DDB2 and
repaired by Global Genome Repair (GG-NER) [86]. Patients with defects in this pathway show the
characteristic UV sensitivity and skin cancer associated with Xeroderma Pigmentosum (XP), but
these patients rarely show neurological symptoms [87]. Conversely, if these lesions lie in transcribed
regions of the genome, RNA Polymerase stalling signals the recruitment of repair factors in the
transcription-coupled NER (TC-NER) pathway. Components specific to processing stalled RNA
polymerase and TC-NER are CSA and CSB, with subsequent steps common to both NER pathways
and involving unwinding DNA around the lesion (by XPB/XPD), excising a region of DNA flanking the
lesion (by ERCC1-XPF/XPG), and DNA synthesis using the complementary (non-damaged) strand as a
template (by PCNA/Pol //) [88-92] . Patients with defective TC-NER do not develop cancer, but
suffer from XP, Cockayne’s syndrome (CS), or trichothiodystrophy (TTD). These result in a spectrum
of neurological phenotypes, including microcephaly, progressive neurological impairment, ataxia,
brittle hair and ichthiosis with variable onset and severity [93-97].
Although CS and XP mouse models initially failed to reproduce the neurodegenerative symptoms
seen in patients [98-101], combining NER mutants leads to a more severe neurological phenotype
that specifically targets the cerebellum during post-natal development [102, 103]. For example, Xpa-
/-/Csb-/- mice develop ataxia within 1 week of birth following decreased cell proliferation and
increased apoptosis in the external granular layer of the cerebellum [103].
4.2 Single-strand break repair (SSBR)
Single-strand break repair (SSBR) has evolved in vertebrates to detect and repair the many
thousands of nicks and single-stranded gaps caused by cellular genotoxic events [104]. Deficiency in
SSBR leads to cellular sensitivity to radiation, oxidative stress and base damaging agents [105, 106].
PARP1 is the sensor of chromosomal SSBs, and results in accumulation of SSBR proteins such as the
XRCC1/DNA Ligase III (Lig3) heterodimer at sites of DNA damage [107, 108]. XRCC1/Lig3 appears to
assemble or recruit a number of DNA processing factors at sites of SSBs, such as Aprataxin, TDP1,
PNKP, and DNA pol , [109-111]. In mice, Lig3 is essential for mitochondrial DNA maintenance and
embryonic viability [112, 113]. Similarly, XRCC1 is required for embryonic viability [114], though
most likely for its role in nuclear DNA repair [115, 116]. Brain-specific knockout of XRCC1 (Xrcc1Nes-
Cre) results in the severe loss of neurons in the cerebellum and hippocampus. Progressive loss of
proliferating and differentiating interneurons in the EGL of the cerebellum demonstrates a
requirement for SSBR in postnatal brain development and maintenance. Progression of this disease
is rapid, with mice developing ataxia from several weeks old and dying at around 4 months, most
likely as a result of episodic seizures [117]. As discussed above, this likely reflects the importance of
Xrcc1 for repair of all types of SSB, and thus the saturation of HR capacity during S phase in Xrcc1-
defective proliferating cells, during neurodevelopment.
4.2.1 Ataxia with oculomotor apraxia-1 (AOA1)
Patients with ataxia resulting from mutant XRCC1 have yet to be found, but there are several cases
of cerebellar ataxia resulting from less severe defects in SSBR. Neurological symptoms resemble
those seen in Xrcc1Nes-Cre mice, and overlap with those of A-T patients. These diseases can be
distinguished from A-T, however, because patients do not display extra-neurological features. The
most common disorder associated with defects in SSBR is ataxia oculomotor apraxia-1 (EAOH or
AOA1), which exhibits progressive cerebellar ataxia from 3-10 years. The disease is caused by the
loss of functional aprataxin [118, 119], a protein that interacts directly with XRCC1 via an amino-
terminal FHA domain. APTX is involved in the end processing step of SSBR (see Fig.4), during which it
removes AMP from the 5’-termini of DNA breaks resulting from abortive DNA ligation events [120-
122]. Aprataxin-deficient neuronal cells are deficient in short-patch SSBR [122] and show sensitivity
to genotoxic agents [123]. It should be noted that APTX also interacts with XRCC4, via its FHA
domain, and thus is most likely also involved in DSB repair by NHEJ. However, to date, a defect in the
repair of cellular DSBs in APTX defective cells has not been observed [122, 124]. Unfortunately,
similar to A-T, the neurodegenerative pathology observed in AOA1 patients is not recapitulated in
Aptx -/- mice, highlighting the difficulty in studying progressive DNA damage-induced
neurodegeneration in the mouse.
4.2.2 Spinocerebellar ataxia with axonal neuropathy (SCAN1)
Spinocerebellar ataxia with axonal neuropathy (SCAN1), results in cerebellar ataxia from around 15
years old, and caused by the loss of functional tyrosyl-DNA phosphodiesterase 1 (TDP1). This protein
interacts with XRCC1/Lig3 heterodimer via direct interaction with Lig3, and is also involved in the
end processing step of SSBR [125]. TDP1 removes trapped topoisomerase peptides from 3’-termini
of DNA breaks resulting from abortive topoisomerase I (TOP1) activity [125, 126], and is also active
on other types of 3’-modified termini [127, 128]. Loss of this protein results in reduced rates of
cellular SSBR and sensitivity to a range of genotoxic agents, but to date has not been reported to
result in reduced rates of DSB repair [125, 129]. Tdp1 -/- mice show late-onset progressive atrophy
in the cerebellum, consistent with a SCAN1 phenotype [130].
Mechanistically similar to TDP1, tyrosyl-DNA phosphodiesterase 2 (TDP2) acts at sites of aborted
Topoisomerase II (TOP2) and processes phosphotyrosyl-peptides on the 5’-ends of DSBs [131]. There
are so far no clinical phenotypes for defective processing of these lesions, and Tdp2 -/- do not show
severe neurological symptoms, but a requirement for processing stalled TOP2 during replication
and/or transcription could result in SCAN1-like symptoms in older TDP2 patients.
4.2.3 Microcephaly with Early-Onset Seizures and Developmental Delay (MCSZ)
Polynucleotide kinase/phosphatase (PNKP) resembles aprataxin in the presence of an N-terminal
fork-head associated (FHA) domain that is required for direct interaction with XRCC1 and XRCC4
[110, 132]. PNKP is another DNA end processing factor that processes damaged termini at DNA
strand breaks. In this case the DNA substrates are 5’-hydroxyl and/or 3’-phosphate termini, at either
SSBs [110, 133] or DSBs [132, 134], which require the DNA kinase or DNA phosphatase activity of
PNKP to restore ligatable 5’-phosphate and 3’-hydroxyl termini, respectively [135]. In a similar
manner to aprataxin and TDP1, loss of PNKP phosphatase activity results in delayed repair of cellular
SSBs, and sensitivity to oxidative stress [109, 136]. Patients with mutations in this protein suffer from
microcephaly, early-onset seizures and developmental delay (MCSZ [137]). The spectrum of
neurological symptoms in these patients could represent a very severe SSBR defect that is
reminiscent of Xrcc1Nes-Cre mice with an onset period in late development. This would be consistent
with the observation that ~70% of SSBs arising from endogenous oxidative stress are likely to be
substrates for PNKP [135]. However, it could also reflect the overlapping requirement for PNKP
activity during NHEJ, and thus during neuroprogenitor proliferation. A similar argument could be
made for Tdp1 and APTX, since both of these arguably also can function at sub-sets of DSBs [121,
132]. However, as discussed above, there is little evidence for a defect in DSB re-joining in cells
lacking either APTX or TDP1 [122, 124, 125]. To date, therefore, neurodegeneration in SCAN1 and
AOA1 is most readily explained by the defect in SSB repair, whereas the
neurodevelopmental/seizure pathology observed in MCSZ might reflect a more severe defect in
SSBR and/or and combined defects in both SSBR and DSBR .
4.3 Single-strand lesions and neuronal cell death
Single-strand lesions are not believed to activate apoptotic pathways directly, but accumulation of
CPDs, 6-4 PPs, stalled topoisomerase, SSBs or abasic sites in transcribed DNA regions can slow or
block RNA polymerases [138-142]. There are significant phenotypic overlaps between the SSBR
diseases such as AOA1 and SCAN1 and those resulting from defective RNA processing such as ataxia-
oculomotor apraxia-2 (AOA2) [143, 144], supporting the idea that certain neuronal cells are sensitive
to transcription stalling. Furthermore it has recently been reported that RNA processing and DNA
repair are closely linked at stalled RNA polymerase sites, suggesting a mechanistic link between
these two processes as well as a clinical one [145-147]. The timing and progression of the
neurological pathologies described above varies from case to case, and likely involves numerous
factors including the endogenous level of the specific lesion(s) processed by the relevant protein, the
severity of the mutation, and the level of transcriptional activity within the affected cells or tissues.
High levels of transcription may increase the susceptibility of particular cells in the brain to apoptosis
via stalled transcription, and may explain why particular sensitivity in the cerebellum leads to ataxia.
Accumulation of transcription-blocking lesions could result in the depletion of essential mRNAs and
eventually lead to cell death by a number of indirect means, but alternatively cell death may be
triggered directly via activation of specific sensors and effectors from these lesions (Figure 3). For
example, stalled RNA polymerase II may stimulate p53-mediated apoptosis via ATR, even in the
absence of replication [148-150], possibly via accumulation of RPA on regions of single-stranded
DNA [151]. Activation of PARP at SSBs can trigger another mechanism of cell death. Prolonged
activation leads to accumulation of cellular poly(ADP-ribose) (PAR) and depletion of NAD+, which
can stimulate the release of apoptosis-inducing factor from mitochondria, resulting in a PARP-
dependent, p53-independent, form of cell death known as parthanatos [152-154]. Neuronal cells
seem to be particularly sensitive to PARP-induced cell death, as illustrated in models of cerebral
ischemia [155, 156]. Again, high levels of oxidative stress and PARP activity may confer
hypersensitivity of certain regions of the brain to single-strand damage.
5 Conclusion
Recent data from transgenic models has enabled us to resolve the overlapping neurological
phenotypes in DNA repair disorders. As illustrated in figure 1, these disorders can be categorised
into early developmental (embryonic lethality) mid-to-late developmental (microcephaly) or post-
developmental (neurodegenerative). Broadly-speaking, these categories are defined by the repair
pathway that is defective, with a requirement for HR particularly evident during early development,
NHEJ during late development, and repair of single-strand lesions for post-developmental
maintenance. However, exceptions to this general rule are evident. For example, very severe defects
in SSBR such as those observed in Xrcc1-defective mice, and possibly in PNKP-defective MCSZ
patients, may saturate alternative (homologous recombination-mediated) repair mechanisms in
proliferating cells and thereby result in neurodevelopmental defects and microcephaly. In addition,
ATM and MRE11 are involved in DSBR, yet the neural phenotypes of A-T and A-TLD patients are
reminiscent of individuals with defects in the repair of single-strand lesions. Whilst at first glance this
may appear perplexing, there are two possible explanations for this: 1: There may be an as yet
undefined role for ATM and MRN in the repair of single-strand lesions at blocked transcription sites,
or 2: Deficient ATM signalling enables damaged neurons to escape apoptosis with persistent
transcription-blocking lesions, and accumulation of these eventually leads to cell death by the
alternative mechanisms described above. Either of these could contribute to the progressive
degenerative pathology similar to that of diseases in which the repair of single-strand lesions is
defective.
6 References
[1] T. Lindahl, Instability and decay of the primary structure of DNA, Nature, 362 (1993) 709-715.
[2] J.R. Mitchell, J.H. Hoeijmakers, L.J. Niedernhofer, Divide and conquer: nucleotide excision repair
battles cancer and ageing, Curr Opin Cell Biol, 15 (2003) 232-240.
[3] J. Rouse, S.P. Jackson, Interfaces between the detection, signaling, and repair of DNA damage,
Science, 297 (2002) 547-551.
[4] J.H. Hoeijmakers, Genome maintenance mechanisms for preventing cancer, Nature, 411 (2001)
366-374.
[5] M. O'Driscoll, P.A. Jeggo, The role of double-strand break repair - insights from human genetics,
Nat Rev Genet, 7 (2006) 45-54.
[6] P.J. McKinnon, K.W. Caldecott, DNA strand break repair and human genetic disease, Annu Rev
Genomics Hum Genet, 8 (2007) 37-55.
[7] J.H. Hoeijmakers, DNA damage, aging, and cancer, N Engl J Med, 361 (2009) 1475-1485.
[8] L.G. Morris, S. Veeriah, T.A. Chan, Genetic determinants at the interface of cancer and
neurodegenerative disease, Oncogene, 29 (2010) 3453-3464.
[9] R.L. Sidman, P. Rakic, Neuronal migration, with special reference to developing human brain: a
review, Brain Res, 62 (1973) 1-35.
[10] N. Zecevic, F. Hu, I. Jakovcevski, Interneurons in the developing human neocortex, Dev
Neurobiol, 71 (2011) 18-33.
[11] K. Letinic, R. Zoncu, P. Rakic, Origin of GABAergic neurons in the human neocortex, Nature, 417
(2002) 645-649.
[12] B.E. Lamonica, J.H. Lui, X. Wang, A.R. Kriegstein, OSVZ progenitors in the human cortex: an
updated perspective on neurodevelopmental disease, Curr Opin Neurobiol, (2012).
[13] N. Sanai, T. Nguyen, R.A. Ihrie, Z. Mirzadeh, H.H. Tsai, M. Wong, N. Gupta, M.S. Berger, E.
Huang, J.M. Garcia-Verdugo, D.H. Rowitch, A. Alvarez-Buylla, Corridors of migrating neurons in the
human brain and their decline during infancy, Nature, 478 (2011) 382-386.
[14] N. Bayatti, J.A. Moss, L. Sun, P. Ambrose, J.F. Ward, S. Lindsay, G.J. Clowry, A molecular
neuroanatomical study of the developing human neocortex from 8 to 17 postconceptional weeks
revealing the early differentiation of the subplate and subventricular zone, Cereb Cortex, 18 (2008)
1536-1548.
[15] N. Zecevic, Y. Chen, R. Filipovic, Contributions of cortical subventricular zone to the
development of the human cerebral cortex, J Comp Neurol, 491 (2005) 109-122.
[16] S.P. Jackson, Sensing and repairing DNA double-strand breaks, Carcinogenesis, 23 (2002) 687-
696.
[17] M.R. Lieber, The mechanism of double-strand DNA break repair by the nonhomologous DNA
end-joining pathway, Annu Rev Biochem, 79 (2010) 181-211.
[18] E. Weterings, D.J. Chen, The endless tale of non-homologous end-joining, Cell Res, 18 (2008)
114-124.
[19] M.E. Moynahan, M. Jasin, Mitotic homologous recombination maintains genomic stability and
suppresses tumorigenesis, Nat Rev Mol Cell Biol, 11 (2010) 196-207.
[20] Z. Mao, M. Bozzella, A. Seluanov, V. Gorbunova, DNA repair by nonhomologous end joining and
homologous recombination during cell cycle in human cells, Cell Cycle, 7 (2008) 2902-2906.
[21] E. Sonoda, H. Hochegger, A. Saberi, Y. Taniguchi, S. Takeda, Differential usage of non-
homologous end-joining and homologous recombination in double strand break repair, DNA Repair
(Amst), 5 (2006) 1021-1029.
[22] K.E. Orii, Y. Lee, N. Kondo, P.J. McKinnon, Selective utilization of nonhomologous end-joining
and homologous recombination DNA repair pathways during nervous system development, Proc
Natl Acad Sci U S A, 103 (2006) 10017-10022.
[23] B.P. Alter, P.S. Rosenberg, L.C. Brody, Clinical and molecular features associated with biallelic
mutations in FANCD1/BRCA2, J Med Genet, 44 (2007) 1-9.
[24] K.R. Fattah, B.L. Ruis, E.A. Hendrickson, Mutations to Ku reveal differences in human somatic
cell lines, DNA Repair (Amst), 7 (2008) 762-774.
[25] G. Li, C. Nelsen, E.A. Hendrickson, Ku86 is essential in human somatic cells, Proc Natl Acad Sci U
S A, 99 (2002) 832-837.
[26] D. Buck, L. Malivert, R. de Chasseval, A. Barraud, M.C. Fondaneche, O. Sanal, A. Plebani, J.L.
Stephan, M. Hufnagel, F. le Deist, A. Fischer, A. Durandy, J.P. de Villartay, P. Revy, Cernunnos, a novel
nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly, Cell,
124 (2006) 287-299.
[27] M. O'Driscoll, K.M. Cerosaletti, P.M. Girard, Y. Dai, M. Stumm, B. Kysela, B. Hirsch, A. Gennery,
S.E. Palmer, J. Seidel, R.A. Gatti, R. Varon, M.A. Oettinger, H. Neitzel, P.A. Jeggo, P. Concannon, DNA
ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency, Mol
Cell, 8 (2001) 1175-1185.
[28] M. van der Burg, H. Ijspeert, N.S. Verkaik, T. Turul, W.W. Wiegant, K. Morotomi-Yano, P.O. Mari,
I. Tezcan, D.J. Chen, M.Z. Zdzienicka, J.J. van Dongen, D.C. van Gent, A DNA-PKcs mutation in a
radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining, J Clin
Invest, 119 (2009) 91-98.
[29] A. Nussenzweig, C. Chen, V. da Costa Soares, M. Sanchez, K. Sokol, M.C. Nussenzweig, G.C. Li,
Requirement for Ku80 in growth and immunoglobulin V(D)J recombination, Nature, 382 (1996) 551-
555.
[30] H. Ouyang, A. Nussenzweig, A. Kurimasa, V.C. Soares, X. Li, C. Cordon-Cardo, W. Li, N. Cheong,
M. Nussenzweig, G. Iliakis, D.J. Chen, G.C. Li, Ku70 is required for DNA repair but not for T cell
antigen receptor gene recombination In vivo, J Exp Med, 186 (1997) 921-929.
[31] D.E. Barnes, G. Stamp, I. Rosewell, A. Denzel, T. Lindahl, Targeted disruption of the gene
encoding DNA ligase IV leads to lethality in embryonic mice, Curr Biol, 8 (1998) 1395-1398.
[32] K.M. Frank, J.M. Sekiguchi, K.J. Seidl, W. Swat, G.A. Rathbun, H.L. Cheng, L. Davidson, L.
Kangaloo, F.W. Alt, Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA
ligase IV, Nature, 396 (1998) 173-177.
[33] Y. Gao, Y. Sun, K.M. Frank, P. Dikkes, Y. Fujiwara, K.J. Seidl, J.M. Sekiguchi, G.A. Rathbun, W.
Swat, J. Wang, R.T. Bronson, B.A. Malynn, M. Bryans, C. Zhu, J. Chaudhuri, L. Davidson, R. Ferrini, T.
Stamato, S.H. Orkin, M.E. Greenberg, F.W. Alt, A critical role for DNA end-joining proteins in both
lymphogenesis and neurogenesis, Cell, 95 (1998) 891-902.
[34] Y. Shiloh, ATM and ATR: networking cellular responses to DNA damage, Curr Opin Genet Dev, 11
(2001) 71-77.
[35] D. Durocher, S.P. Jackson, DNA-PK, ATM and ATR as sensors of DNA damage: variations on a
theme?, Curr Opin Cell Biol, 13 (2001) 225-231.
[36] D. Shechter, V. Costanzo, J. Gautier, ATR and ATM regulate the timing of DNA replication origin
firing, Nat Cell Biol, 6 (2004) 648-655.
[37] R.T. Abraham, Cell cycle checkpoint signaling through the ATM and ATR kinases, Genes Dev, 15
(2001) 2177-2196.
[38] K.M. Frank, N.E. Sharpless, Y. Gao, J.M. Sekiguchi, D.O. Ferguson, C. Zhu, J.P. Manis, J. Horner,
R.A. DePinho, F.W. Alt, DNA ligase IV deficiency in mice leads to defective neurogenesis and
embryonic lethality via the p53 pathway, Mol Cell, 5 (2000) 993-1002.
[39] S.A. Gatz, L. Ju, R. Gruber, E. Hoffmann, A.M. Carr, Z.Q. Wang, C. Liu, P.A. Jeggo, Requirement
for DNA ligase IV during embryonic neuronal development, J Neurosci, 31 (2011) 10088-10100.
[40] Y. Lee, M.J. Chong, P.J. McKinnon, Ataxia telangiectasia mutated-dependent apoptosis after
genotoxic stress in the developing nervous system is determined by cellular differentiation status, J
Neurosci, 21 (2001) 6687-6693.
[41] A.M. Taylor, P.J. Byrd, Molecular pathology of ataxia telangiectasia, J Clin Pathol, 58 (2005)
1009-1015.
[42] N.D. Lakin, P. Weber, T. Stankovic, S.T. Rottinghaus, A.M. Taylor, S.P. Jackson, Analysis of the
ATM protein in wild-type and ataxia telangiectasia cells, Oncogene, 13 (1996) 2707-2716.
[43] P.O. Frappart, P.J. McKinnon, Ataxia-telangiectasia and related diseases, Neuromolecular Med,
8 (2006) 495-511.
[44] H.V. Vinters, R.A. Gatti, P. Rakic, Sequence of cellular events in cerebellar ontogeny relevant to
expression of neuronal abnormalities in ataxia-telangiectasia, Kroc Found Ser, 19 (1985) 233-255.
[45] M.M. Paula-Barbosa, C. Ruela, M.A. Tavares, C. Pontes, A. Saraiva, C. Cruz, Cerebellar cortex
ultrastructure in ataxia-telangiectasia, Ann Neurol, 13 (1983) 297-302.
[46] M.M. Verhagen, J.J. Martin, M. van Deuren, C. Ceuterick-de Groote, C.M. Weemaes, B.H.
Kremer, M.A. Taylor, M.A. Willemsen, M. Lammens, Neuropathology in classical and variant ataxia-
telangiectasia, Neuropathology, 32 (2012) 234-244.
[47] C. Barlow, S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J.N. Crawley, T.
Ried, D. Tagle, A. Wynshaw-Boris, Atm-deficient mice: a paradigm of ataxia telangiectasia, Cell, 86
(1996) 159-171.
[48] Y. Xu, T. Ashley, E.E. Brainerd, R.T. Bronson, M.S. Meyn, D. Baltimore, Targeted disruption of
ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and
thymic lymphoma, Genes Dev, 10 (1996) 2411-2422.
[49] L. Zou, S.J. Elledge, Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes,
Science, 300 (2003) 1542-1548.
[50] K.M. Sleeth, C.S. Sorensen, N. Issaeva, J. Dziegielewski, J. Bartek, T. Helleday, RPA mediates
recombination repair during replication stress and is displaced from DNA by checkpoint signalling in
human cells, J Mol Biol, 373 (2007) 38-47.
[51] R.G. Syljuasen, C.S. Sorensen, L.T. Hansen, K. Fugger, C. Lundin, F. Johansson, T. Helleday, M.
Sehested, J. Lukas, J. Bartek, Inhibition of human Chk1 causes increased initiation of DNA replication,
phosphorylation of ATR targets, and DNA breakage, Mol Cell Biol, 25 (2005) 3553-3562.
[52] J. Goodship, H. Gill, J. Carter, A. Jackson, M. Splitt, M. Wright, Autozygosity mapping of a seckel
syndrome locus to chromosome 3q22. 1-q24, Am J Hum Genet, 67 (2000) 498-503.
[53] M. O'Driscoll, V.L. Ruiz-Perez, C.G. Woods, P.A. Jeggo, J.A. Goodship, A splicing mutation
affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel
syndrome, Nat Genet, 33 (2003) 497-501.
[54] E.J. Brown, D. Baltimore, ATR disruption leads to chromosomal fragmentation and early
embryonic lethality, Genes Dev, 14 (2000) 397-402.
[55] A. de Klein, M. Muijtjens, R. van Os, Y. Verhoeven, B. Smit, A.M. Carr, A.R. Lehmann, J.H.
Hoeijmakers, Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic
lethality in mice, Curr Biol, 10 (2000) 479-482.
[56] M. Murga, S. Bunting, M.F. Montana, R. Soria, F. Mulero, M. Canamero, Y. Lee, P.J. McKinnon, A.
Nussenzweig, O. Fernandez-Capetillo, A mouse model of ATR-Seckel shows embryonic replicative
stress and accelerated aging, Nat Genet, 41 (2009) 891-898.
[57] Y. Lee, E.R. Shull, P.O. Frappart, S. Katyal, V. Enriquez-Rios, J. Zhao, H.R. Russell, E.J. Brown, P.J.
McKinnon, ATR maintains select progenitors during nervous system development, Embo J, 31 (2012)
1177-1189.
[58] G.K. Alderton, L. Galbiati, E. Griffith, K.H. Surinya, H. Neitzel, A.P. Jackson, P.A. Jeggo, M.
O'Driscoll, Regulation of mitotic entry by microcephalin and its overlap with ATR signalling, Nat Cell
Biol, 8 (2006) 725-733.
[59] E. Griffith, S. Walker, C.A. Martin, P. Vagnarelli, T. Stiff, B. Vernay, N. Al Sanna, A. Saggar, B.
Hamel, W.C. Earnshaw, P.A. Jeggo, A.P. Jackson, M. O'Driscoll, Mutations in pericentrin cause Seckel
syndrome with defective ATR-dependent DNA damage signaling, Nat Genet, 40 (2008) 232-236.
[60] R. Gruber, Z. Zhou, M. Sukchev, T. Joerss, P.O. Frappart, Z.Q. Wang, MCPH1 regulates the
neuroprogenitor division mode by coupling the centrosomal cycle with mitotic entry through the
Chk1-Cdc25 pathway, Nat Cell Biol, 13 (2011) 1325-1334.
[61] B. Delaval, S.J. Doxsey, Pericentrin in cellular function and disease, J Cell Biol, 188 (2010) 181-
190.
[62] F. Moreno-Herrero, M. de Jager, N.H. Dekker, R. Kanaar, C. Wyman, C. Dekker, Mesoscale
conformational changes in the DNA-repair complex Rad50/Mre11/Nbs1 upon binding DNA, Nature,
437 (2005) 440-443.
[63] T. Stiff, C. Reis, G.K. Alderton, L. Woodbine, M. O'Driscoll, P.A. Jeggo, Nbs1 is required for ATR-
dependent phosphorylation events, Embo J, 24 (2005) 199-208.
[64] T. Uziel, Y. Lerenthal, L. Moyal, Y. Andegeko, L. Mittelman, Y. Shiloh, Requirement of the MRN
complex for ATM activation by DNA damage, Embo J, 22 (2003) 5612-5621.
[65] R.S. Williams, J.A. Tainer, A nanomachine for making ends meet: MRN is a flexing scaffold for
the repair of DNA double-strand breaks, Mol Cell, 19 (2005) 724-726.
[66] T.T. Paull, M. Gellert, The 3' to 5' exonuclease activity of Mre 11 facilitates repair of DNA
double-strand breaks, Mol Cell, 1 (1998) 969-979.
[67] I.B. Resnick, I. Kondratenko, E. Pashanov, A.A. Maschan, A. Karachunsky, O. Togoev, A. Timakov,
A. Polyakov, S. Tverskaya, O. Evgrafov, A.G. Roumiantsev, 657del5 mutation in the gene for
Nijmegen breakage syndrome (NBS1) in a cohort of Russian children with lymphoid tissue
malignancies and controls, Am J Med Genet A, 120A (2003) 174-179.
[68] R. Varon, C. Vissinga, M. Platzer, K.M. Cerosaletti, K.H. Chrzanowska, K. Saar, G. Beckmann, E.
Seemanova, P.R. Cooper, N.J. Nowak, M. Stumm, C.M. Weemaes, R.A. Gatti, R.K. Wilson, M.
Digweed, A. Rosenthal, K. Sperling, P. Concannon, A. Reis, Nibrin, a novel DNA double-strand break
repair protein, is mutated in Nijmegen breakage syndrome, Cell, 93 (1998) 467-476.
[69] G.S. Stewart, R.S. Maser, T. Stankovic, D.A. Bressan, M.I. Kaplan, N.G. Jaspers, A. Raams, P.J.
Byrd, J.H. Petrini, A.M. Taylor, The DNA double-strand break repair gene hMRE11 is mutated in
individuals with an ataxia-telangiectasia-like disorder, Cell, 99 (1999) 577-587.
[70] R. Waltes, R. Kalb, M. Gatei, A.W. Kijas, M. Stumm, A. Sobeck, B. Wieland, R. Varon, Y. Lerenthal,
M.F. Lavin, D. Schindler, T. Dork, Human RAD50 deficiency in a Nijmegen breakage syndrome-like
disorder, Am J Hum Genet, 84 (2009) 605-616.
[71] G. Barbi, J.M. Scheres, D. Schindler, R.D. Taalman, K. Rodens, K. Mehnert, M. Muller, H.
Seyschab, Chromosome instability and X-ray hypersensitivity in a microcephalic and growth-retarded
child, Am J Med Genet, 40 (1991) 44-50.
[72] S. Matsuura, H. Tauchi, A. Nakamura, N. Kondo, S. Sakamoto, S. Endo, D. Smeets, B. Solder, B.H.
Belohradsky, V.M. Der Kaloustian, M. Oshimura, M. Isomura, Y. Nakamura, K. Komatsu, Positional
cloning of the gene for Nijmegen breakage syndrome, Nat Genet, 19 (1998) 179-181.
[73] J. Zhu, S. Petersen, L. Tessarollo, A. Nussenzweig, Targeted disruption of the Nijmegen breakage
syndrome gene NBS1 leads to early embryonic lethality in mice, Curr Biol, 11 (2001) 105-109.
[74] G. Luo, M.S. Yao, C.F. Bender, M. Mills, A.R. Bladl, A. Bradley, J.H. Petrini, Disruption of mRad50
causes embryonic stem cell lethality, abnormal embryonic development, and sensitivity to ionizing
radiation, Proc Natl Acad Sci U S A, 96 (1999) 7376-7381.
[75] J. Buis, Y. Wu, Y. Deng, J. Leddon, G. Westfield, M. Eckersdorff, J.M. Sekiguchi, S. Chang, D.O.
Ferguson, Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct
from ATM activation, Cell, 135 (2008) 85-96.
[76] B.R. Williams, O.K. Mirzoeva, W.F. Morgan, J. Lin, W. Dunnick, J.H. Petrini, A murine model of
Nijmegen breakage syndrome, Curr Biol, 12 (2002) 648-653.
[77] J.W. Theunissen, M.I. Kaplan, P.A. Hunt, B.R. Williams, D.O. Ferguson, F.W. Alt, J.H. Petrini,
Checkpoint failure and chromosomal instability without lymphomagenesis in Mre11(ATLD1/ATLD1)
mice, Mol Cell, 12 (2003) 1511-1523.
[78] E.R. Shull, Y. Lee, H. Nakane, T.H. Stracker, J. Zhao, H.R. Russell, J.H. Petrini, P.J. McKinnon,
Differential DNA damage signaling accounts for distinct neural apoptotic responses in ATLD and NBS,
Genes Dev, 23 (2009) 171-180.
[79] P.J. McKinnon, ATM and the molecular pathogenesis of ataxia telangiectasia, Annu Rev Pathol, 7
(2012) 303-321.
[80] A.R. Lehmann, DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome
and trichothiodystrophy, Biochimie, 85 (2003) 1101-1111.
[81] B. Schumacher, Transcription-blocking DNA damage in aging: a mechanism for hormesis,
Bioessays, 31 (2009) 1347-1356.
[82] A. Kuzminov, Single-strand interruptions in replicating chromosomes cause double-strand
breaks, Proc Natl Acad Sci U S A, 98 (2001) 8241-8246.
[83] J. de Boer, J.H. Hoeijmakers, Nucleotide excision repair and human syndromes, Carcinogenesis,
21 (2000) 453-460.
[84] T. Thorslund, C. von Kobbe, J.A. Harrigan, F.E. Indig, M. Christiansen, T. Stevnsner, V.A. Bohr,
Cooperation of the Cockayne syndrome group B protein and poly(ADP-ribose) polymerase 1 in the
response to oxidative stress, Mol Cell Biol, 25 (2005) 7625-7636.
[85] M. Osterod, E. Larsen, F. Le Page, J.G. Hengstler, G.T. Van Der Horst, S. Boiteux, A. Klungland, B.
Epe, A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can
prevent the in vivo accumulation of endogenous oxidative DNA base damage, Oncogene, 21 (2002)
8232-8239.
[86] K. Sugasawa, J.M. Ng, C. Masutani, S. Iwai, P.J. van der Spek, A.P. Eker, F. Hanaoka, D. Bootsma,
J.H. Hoeijmakers, Xeroderma pigmentosum group C protein complex is the initiator of global
genome nucleotide excision repair, Mol Cell, 2 (1998) 223-232.
[87] D. Bootsma, J.H. Hoeijmakers, The genetic basis of xeroderma pigmentosum, Ann Genet, 34
(1991) 143-150.
[88] V.A. Bohr, C.A. Smith, D.S. Okumoto, P.C. Hanawalt, DNA repair in an active gene: removal of
pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome
overall, Cell, 40 (1985) 359-369.
[89] I. Mellon, G. Spivak, P.C. Hanawalt, Selective removal of transcription-blocking DNA damage
from the transcribed strand of the mammalian DHFR gene, Cell, 51 (1987) 241-249.
[90] D. Mu, A. Sancar, Model for XPC-independent transcription-coupled repair of pyrimidine dimers
in humans, J Biol Chem, 272 (1997) 7570-7573.
[91] C.L. Licht, T. Stevnsner, V.A. Bohr, Cockayne syndrome group B cellular and biochemical
functions, Am J Hum Genet, 73 (2003) 1217-1239.
[92] T. Ogi, A.R. Lehmann, The Y-family DNA polymerase kappa (pol kappa) functions in mammalian
nucleotide-excision repair, Nat Cell Biol, 8 (2006) 640-642.
[93] M.A. Nance, S.A. Berry, Cockayne syndrome: review of 140 cases, Am J Med Genet, 42 (1992)
68-84.
[94] M. Stefanini, P. Lagomarsini, C.F. Arlett, S. Marinoni, C. Borrone, F. Crovato, G. Trevisan, G.
Cordone, F. Nuzzo, Xeroderma pigmentosum (complementation group D) mutation is present in
patients affected by trichothiodystrophy with photosensitivity, Hum Genet, 74 (1986) 107-112.
[95] G. Weeda, A.W. Hutter, K.H. Groenier, J. Schuling, The workload of trainees in general practice,
Med Educ, 31 (1997) 138-143.
[96] K.A. Henning, L. Li, N. Iyer, L.D. McDaniel, M.S. Reagan, R. Legerski, R.A. Schultz, M. Stefanini,
A.R. Lehmann, L.V. Mayne, E.C. Friedberg, The Cockayne syndrome group A gene encodes a WD
repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH, Cell, 82
(1995) 555-564.
[97] D.L. Mallery, B. Tanganelli, S. Colella, H. Steingrimsdottir, A.J. van Gool, C. Troelstra, M.
Stefanini, A.R. Lehmann, Molecular analysis of mutations in the CSB (ERCC6) gene in patients with
Cockayne syndrome, Am J Hum Genet, 62 (1998) 77-85.
[98] A. de Vries, C.T. van Oostrom, F.M. Hofhuis, P.M. Dortant, R.J. Berg, F.R. de Gruijl, P.W. Wester,
C.F. van Kreijl, P.J. Capel, H. van Steeg, et al., Increased susceptibility to ultraviolet-B and carcinogens
of mice lacking the DNA excision repair gene XPA, Nature, 377 (1995) 169-173.
[99] H. Nakane, S. Takeuchi, S. Yuba, M. Saijo, Y. Nakatsu, H. Murai, Y. Nakatsuru, T. Ishikawa, S.
Hirota, Y. Kitamura, et al., High incidence of ultraviolet-B-or chemical-carcinogen-induced skin
tumours in mice lacking the xeroderma pigmentosum group A gene, Nature, 377 (1995) 165-168.
[100] G.T. van der Horst, H. van Steeg, R.J. Berg, A.J. van Gool, J. de Wit, G. Weeda, H. Morreau, R.B.
Beems, C.F. van Kreijl, F.R. de Gruijl, D. Bootsma, J.H. Hoeijmakers, Defective transcription-coupled
repair in Cockayne syndrome B mice is associated with skin cancer predisposition, Cell, 89 (1997)
425-435.
[101] J. de Boer, H. van Steeg, R.J. Berg, J. Garssen, J. de Wit, C.T. van Oostrum, R.B. Beems, G.T. van
der Horst, C.F. van Kreijl, F.R. de Gruijl, D. Bootsma, J.H. Hoeijmakers, G. Weeda, Mouse model for
the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition,
Cancer Res, 59 (1999) 3489-3494.
[102] I. Revet, L. Feeney, A.A. Tang, E.J. Huang, J.E. Cleaver, Dysmyelination not demyelination
causes neurological symptoms in preweaned mice in a murine model of Cockayne syndrome, Proc
Natl Acad Sci U S A, 109 (2012) 4627-4632.
[103] M. Murai, Y. Enokido, N. Inamura, M. Yoshino, Y. Nakatsu, G.T. van der Horst, J.H. Hoeijmakers,
K. Tanaka, H. Hatanaka, Early postnatal ataxia and abnormal cerebellar development in mice lacking
Xeroderma pigmentosum Group A and Cockayne syndrome Group B DNA repair genes, Proc Natl
Acad Sci U S A, 98 (2001) 13379-13384.
[104] K.W. Caldecott, Single-strand break repair and genetic disease, Nat Rev Genet, 9 (2008) 619-
631.
[105] P.A. Jeggo, J. Tesmer, D.J. Chen, Genetic analysis of ionising radiation sensitive mutants of
cultured mammalian cell lines, Mutat Res, 254 (1991) 125-133.
[106] O. Cantoni, D. Murray, R.E. Meyn, Induction and repair of DNA single-strand breaks in EM9
mutant CHO cells treated with hydrogen peroxide, Chem Biol Interact, 63 (1987) 29-38.
[107] S. Okano, L. Lan, K.W. Caldecott, T. Mori, A. Yasui, Spatial and temporal cellular responses to
single-strand breaks in human cells, Mol Cell Biol, 23 (2003) 3974-3981.
[108] S.F. El-Khamisy, M. Masutani, H. Suzuki, K.W. Caldecott, A requirement for PARP-1 for the
assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage, Nucleic Acids Res, 31
(2003) 5526-5533.
[109] C. Breslin, K.W. Caldecott, DNA 3'-phosphatase activity is critical for rapid global rates of single-
strand break repair following oxidative stress, Mol Cell Biol, 29 (2009) 4653-4662.
[110] J.I. Loizou, S.F. El-Khamisy, A. Zlatanou, D.J. Moore, D.W. Chan, J. Qin, S. Sarno, F. Meggio, L.A.
Pinna, K.W. Caldecott, The protein kinase CK2 facilitates repair of chromosomal DNA single-strand
breaks, Cell, 117 (2004) 17-28.
[111] K.W. Caldecott, Mammalian single-strand break repair: mechanisms and links with chromatin,
DNA Repair (Amst), 6 (2007) 443-453.
[112] Y. Gao, S. Katyal, Y. Lee, J. Zhao, J.E. Rehg, H.R. Russell, P.J. McKinnon, DNA ligase III is critical
for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair, Nature, 471 (2011) 240-244.
[113] N. Puebla-Osorio, D.B. Lacey, F.W. Alt, C. Zhu, Early embryonic lethality due to targeted
inactivation of DNA ligase III, Mol Cell Biol, 26 (2006) 3935-3941.
[114] R.S. Tebbs, M.L. Flannery, J.J. Meneses, A. Hartmann, J.D. Tucker, L.H. Thompson, J.E. Cleaver,
R.A. Pedersen, Requirement for the Xrcc1 DNA base excision repair gene during early mouse
development, Dev Biol, 208 (1999) 513-529.
[115] K.W. Caldecott, C.K. McKeown, J.D. Tucker, S. Ljungquist, L.H. Thompson, An interaction
between the mammalian DNA repair protein XRCC1 and DNA ligase III, Mol Cell Biol, 14 (1994) 68-
76.
[116] U. Lakshmipathy, C. Campbell, Mitochondrial DNA ligase III function is independent of Xrcc1,
Nucleic Acids Res, 28 (2000) 3880-3886.
[117] Y. Lee, S. Katyal, Y. Li, S.F. El-Khamisy, H.R. Russell, K.W. Caldecott, P.J. McKinnon, The genesis
of cerebellar interneurons and the prevention of neural DNA damage require XRCC1, Nat Neurosci,
12 (2009) 973-980.
[118] H. Date, O. Onodera, H. Tanaka, K. Iwabuchi, K. Uekawa, S. Igarashi, R. Koike, T. Hiroi, T. Yuasa,
Y. Awaya, T. Sakai, T. Takahashi, H. Nagatomo, Y. Sekijima, I. Kawachi, Y. Takiyama, M. Nishizawa, N.
Fukuhara, K. Saito, S. Sugano, S. Tsuji, Early-onset ataxia with ocular motor apraxia and
hypoalbuminemia is caused by mutations in a new HIT superfamily gene, Nat Genet, 29 (2001) 184-
188.
[119] M.C. Moreira, C. Barbot, N. Tachi, N. Kozuka, E. Uchida, T. Gibson, P. Mendonca, M. Costa, J.
Barros, T. Yanagisawa, M. Watanabe, Y. Ikeda, M. Aoki, T. Nagata, P. Coutinho, J. Sequeiros, M.
Koenig, The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein
aprataxin, Nat Genet, 29 (2001) 189-193.
[120] I. Ahel, U. Rass, S.F. El-Khamisy, S. Katyal, P.M. Clements, P.J. McKinnon, K.W. Caldecott, S.C.
West, The neurodegenerative disease protein aprataxin resolves abortive DNA ligation
intermediates, Nature, 443 (2006) 713-716.
[121] P.M. Clements, C. Breslin, E.D. Deeks, P.J. Byrd, L. Ju, P. Bieganowski, C. Brenner, M.C. Moreira,
A.M. Taylor, K.W. Caldecott, The ataxia-oculomotor apraxia 1 gene product has a role distinct from
ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4, DNA Repair (Amst),
3 (2004) 1493-1502.
[122] J.J. Reynolds, S.F. El-Khamisy, S. Katyal, P. Clements, P.J. McKinnon, K.W. Caldecott, Defective
DNA ligation during short-patch single-strand break repair in ataxia oculomotor apraxia 1, Mol Cell
Biol, 29 (2009) 1354-1362.
[123] N. Gueven, O.J. Becherel, A.W. Kijas, P. Chen, O. Howe, J.H. Rudolph, R. Gatti, H. Date, O.
Onodera, G. Taucher-Scholz, M.F. Lavin, Aprataxin, a novel protein that protects against genotoxic
stress, Hum Mol Genet, 13 (2004) 1081-1093.
[124] S.F. El-Khamisy, S. Katyal, P. Patel, L. Ju, P.J. McKinnon, K.W. Caldecott, Synergistic decrease of
DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin, DNA
Repair (Amst), 8 (2009) 760-766.
[125] S.F. El-Khamisy, G.M. Saifi, M. Weinfeld, F. Johansson, T. Helleday, J.R. Lupski, K.W. Caldecott,
Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1, Nature,
434 (2005) 108-113.
[126] H. Takashima, C.F. Boerkoel, J. John, G.M. Saifi, M.A. Salih, D. Armstrong, Y. Mao, F.A. Quiocho,
B.B. Roa, M. Nakagawa, D.W. Stockton, J.R. Lupski, Mutation of TDP1, encoding a topoisomerase I-
dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy, Nat
Genet, 32 (2002) 267-272.
[127] L. Nilsen, R.J. Forstrom, M. Bjoras, I. Alseth, AP endonuclease independent repair of abasic
sites in Schizosaccharomyces pombe, Nucleic Acids Res, 40 (2012) 2000-2009.
[128] T. Zhou, K. Akopiants, S. Mohapatra, P.S. Lin, K. Valerie, D.A. Ramsden, S.P. Lees-Miller, L.F.
Povirk, Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA
double-strand breaks, DNA Repair (Amst), 8 (2009) 901-911.
[129] J. Murai, S.Y. Huang, B.B. Das, T.S. Dexheimer, S. Takeda, Y. Pommier, Tyrosyl-DNA
phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base
alkylation in vertebrate cells, J Biol Chem, 287 (2012) 12848-12857.
[130] S. Katyal, S.F. el-Khamisy, H.R. Russell, Y. Li, L. Ju, K.W. Caldecott, P.J. McKinnon, TDP1
facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo, Embo J,
26 (2007) 4720-4731.
[131] F. Cortes Ledesma, S.F. El Khamisy, M.C. Zuma, K. Osborn, K.W. Caldecott, A human 5'-tyrosyl
DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage, Nature, 461 (2009) 674-
678.
[132] C.A. Koch, R. Agyei, S. Galicia, P. Metalnikov, P. O'Donnell, A. Starostine, M. Weinfeld, D.
Durocher, Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by
DNA ligase IV, Embo J, 23 (2004) 3874-3885.
[133] C.J. Whitehouse, R.M. Taylor, A. Thistlethwaite, H. Zhang, F. Karimi-Busheri, D.D. Lasko, M.
Weinfeld, K.W. Caldecott, XRCC1 stimulates human polynucleotide kinase activity at damaged DNA
termini and accelerates DNA single-strand break repair, Cell, 104 (2001) 107-117.
[134] C. Chappell, L.A. Hanakahi, F. Karimi-Busheri, M. Weinfeld, S.C. West, Involvement of human
polynucleotide kinase in double-strand break repair by non-homologous end joining, Embo J, 21
(2002) 2827-2832.
[135] A. Jilani, D. Ramotar, C. Slack, C. Ong, X.M. Yang, S.W. Scherer, D.D. Lasko, Molecular cloning of
the human gene, PNKP, encoding a polynucleotide kinase 3'-phosphatase and evidence for its role in
repair of DNA strand breaks caused by oxidative damage, J Biol Chem, 274 (1999) 24176-24186.
[136] J.J. Reynolds, A.K. Walker, E.C. Gilmore, C.A. Walsh, K.W. Caldecott, Impact of PNKP mutations
associated with microcephaly, seizures and developmental delay on enzyme activity and DNA strand
break repair, Nucleic Acids Res, (2012).
[137] J. Shen, E.C. Gilmore, C.A. Marshall, M. Haddadin, J.J. Reynolds, W. Eyaid, A. Bodell, B. Barry, D.
Gleason, K. Allen, V.S. Ganesh, B.S. Chang, A. Grix, R.S. Hill, M. Topcu, K.W. Caldecott, A.J. Barkovich,
C.A. Walsh, Mutations in PNKP cause microcephaly, seizures and defects in DNA repair, Nat Genet,
42 (2010) 245-249.
[138] C. Bendixen, B. Thomsen, J. Alsner, O. Westergaard, Camptothecin-stabilized topoisomerase I-
DNA adducts cause premature termination of transcription, Biochemistry, 29 (1990) 5613-5619.
[139] W. Zhou, P.W. Doetsch, Effects of abasic sites and DNA single-strand breaks on prokaryotic
RNA polymerases, Proc Natl Acad Sci U S A, 90 (1993) 6601-6605.
[140] S.D. Kathe, G.P. Shen, S.S. Wallace, Single-stranded breaks in DNA but not oxidative DNA base
damages block transcriptional elongation by RNA polymerase II in HeLa cell nuclear extracts, J Biol
Chem, 279 (2004) 18511-18520.
[141] B.A. Donahue, R.P. Fuchs, D. Reines, P.C. Hanawalt, Effects of aminofluorene and
acetylaminofluorene DNA adducts on transcriptional elongation by RNA polymerase II, J Biol Chem,
271 (1996) 10588-10594.
[142] L.V. Mayne, A.R. Lehmann, Failure of RNA synthesis to recover after UV irradiation: an early
defect in cells from individuals with Cockayne's syndrome and xeroderma pigmentosum, Cancer Res,
42 (1982) 1473-1478.
[143] I. Le Ber, N. Bouslam, S. Rivaud-Pechoux, J. Guimaraes, A. Benomar, C. Chamayou, C. Goizet,
M.C. Moreira, S. Klur, M. Yahyaoui, Y. Agid, M. Koenig, G. Stevanin, A. Brice, A. Durr, Frequency and
phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients,
Brain, 127 (2004) 759-767.
[144] M.C. Moreira, S. Klur, M. Watanabe, A.H. Nemeth, I. Le Ber, J.C. Moniz, C. Tranchant, P.
Aubourg, M. Tazir, L. Schols, M. Pandolfo, J.B. Schulz, J. Pouget, P. Calvas, M. Shizuka-Ikeda, M. Shoji,
M. Tanaka, L. Izatt, C.E. Shaw, A. M'Zahem, E. Dunne, P. Bomont, T. Benhassine, N. Bouslam, G.
Stevanin, A. Brice, J. Guimaraes, P. Mendonca, C. Barbot, P. Coutinho, J. Sequeiros, A. Durr, J.M.
Warter, M. Koenig, Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular
apraxia 2, Nat Genet, 36 (2004) 225-227.
[145] O. Yuce-Petronczki, S.C. West, Senataxin, defective in the neurogenerative disorder AOA-2, lies
at the interface of transcription and the DNA damage response, Mol Cell Biol, (2012).
[146] K. Skourti-Stathaki, N.J. Proudfoot, N. Gromak, Human senataxin resolves RNA/DNA hybrids
formed at transcriptional pause sites to promote Xrn2-dependent termination, Mol Cell, 42 (2011)
794-805.
[147] H.E. Mischo, B. Gomez-Gonzalez, P. Grzechnik, A.G. Rondon, W. Wei, L. Steinmetz, A. Aguilera,
N.J. Proudfoot, Yeast Sen1 helicase protects the genome from transcription-associated instability,
Mol Cell, 41 (2011) 21-32.
[148] M. Ljungman, F. Zhang, Blockage of RNA polymerase as a possible trigger for u.v. light-induced
apoptosis, Oncogene, 13 (1996) 823-831.
[149] M. Ljungman, F. Zhang, F. Chen, A.J. Rainbow, B.C. McKay, Inhibition of RNA polymerase II as a
trigger for the p53 response, Oncogene, 18 (1999) 583-592.
[150] M.G. Vrouwe, A. Pines, R.M. Overmeer, K. Hanada, L.H. Mullenders, UV-induced photolesions
elicit ATR-kinase-dependent signaling in non-cycling cells through nucleotide excision repair-
dependent and -independent pathways, J Cell Sci, 124 (2011) 435-446.
[151] F.A. Derheimer, H.M. O'Hagan, H.M. Krueger, S. Hanasoge, M.T. Paulsen, M. Ljungman, RPA
and ATR link transcriptional stress to p53, Proc Natl Acad Sci U S A, 104 (2007) 12778-12783.
[152] S.W. Yu, S.A. Andrabi, H. Wang, N.S. Kim, G.G. Poirier, T.M. Dawson, V.L. Dawson, Apoptosis-
inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death, Proc Natl Acad Sci U S
A, 103 (2006) 18314-18319.
[153] S.W. Yu, H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, H.J. Federoff, G.G. Poirier, T.M.
Dawson, V.L. Dawson, Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by
apoptosis-inducing factor, Science, 297 (2002) 259-263.
[154] C.C. Alano, P. Garnier, W. Ying, Y. Higashi, T.M. Kauppinen, R.A. Swanson, NAD+ depletion is
necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death, J Neurosci, 30
(2010) 2967-2978.
[155] M.J. Eliasson, K. Sampei, A.S. Mandir, P.D. Hurn, R.J. Traystman, J. Bao, A. Pieper, Z.Q. Wang,
T.M. Dawson, S.H. Snyder, V.L. Dawson, Poly(ADP-ribose) polymerase gene disruption renders mice
resistant to cerebral ischemia, Nat Med, 3 (1997) 1089-1095.
[156] L. Virag, C. Szabo, The therapeutic potential of poly(ADP-ribose) polymerase inhibitors,
Pharmacol Rev, 54 (2002) 375-429.
7 Figure legends
Figure 1: A model for DNA repair during corticogenesis. A schematic representation of human fetal
cerebral wall sections taken during cortical development at the times shown. Early embryogenesis
depends heavily on homologous recombination (HR) within dividing cells (blue) during rapid growth
phases. Waves of neuroprogenitor division begin from 5-7 weeks within the ventricular zone (VZ)
weeks, and from 12 weeks-6 months after birth in the subventricular zone (SVZ). The red curve
corresponds to waves of migration and differentiation through the intermediate zone (IZ) to the
cortical plate (CP). G1/G0 neuronal cells (red) are dependent on NHEJ for DSBR. Following
differentiation, DSBs are rare and neuronal cells become increasingly dependent on SSBR/TC-NER to
repair frequently occurring single-strand lesions. (Figure adapted from Sidman and Rakic, 1973).
Figure 2: Double strand break repair. Figure shows simplified pathways illustrating the core
components of non-homologous end joining (NHEJ) and homologous recombination (HR). Pathway
choice depends primarily on cell cycle, since HR requires homologous DNA in the sister chromatid to
undergo recombination and can only occur in late S/G2, but NHEJ can occur in G1/early S. Green
boxes show microcephalies resulting from defects in the indicated proteins: Nijmegan Breakage
Syndrome (NBS), NBS-like disorder (NBS-LD), microcephaly, early-onset seizures and developmental
delay (MCSZ), NHEJ1 syndrome, Lig4 Syndrome, Microcephaly 1 (MCPH1), ATR-Seckel Syndrome and
Fanconi anemia complementation group D1 (FANCD1). Yellow boxes show ataxias: Ataxia
telangiectasia (A-T) and A-T-like disorder (A-TLD).
Figure 3: Mechanisms of cell death from unrepaired breaks in neuronal cells. Persistent lesions can
exist as a double strand break (DSB), intrastrand crosslinks (CPD or 6-4 PP), damaged base or single
strand break (SSB). DSBs activate ATM and p53-mediated apoptosis, or via ATR if the cell undergoes
replication (during neurogenesis, for example). Transcription-blocking lesions stall RNA polymerase,
which activates ATR and induces apoptosis via p53, plus there may be indirect effects from depletion
of essential RNAs. In the case of SSBs “parthanatos” is an alternative, p53-independent mechanism
of cell death, in which PARP generates poly(ADP) ribose (PAR), which stimulates mitochondria to
release apoptosis inducing factor (AIF).
Figure 4: Repair of single stranded lesions. Figure shows a simplified model for single strand break
repair (SSBR) and transcription-coupled nucleotide excision repair (TC-NER). The green box shows a
microcephaly (MCSZ) and yellow boxes show ataxias resulting from defects in the indicated proteins:
Cockayne Syndrome, type B (CSB), ataxia with oculomotor apraxia 1 (AOA1), spinocerebellar ataxia
with axonal neuropathy (SCAN1) and Trichothiodystrophy (TTD).
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